11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents

11.3 NSAIDs, Opioids, Corticosteroids & Anti-Gout Agents

Independent Study Guide Notice: Independent study guide by OpenExamPrep. This educational resource is developed independently by OpenExamPrep and is not sponsored, endorsed, or affiliated with the National Board of Podiatric Medical Examiners (NBPME) or Meazure Learning.

---

The Arachidonic Acid Cascade & Cyclooxygenase Isoforms

Following tissue injury, mechanical stress, or surgical incision in the lower extremity, membrane phospholipids are hydrolyzed by Phospholipase $A_2$ ($PLA_2$) into free Arachidonic Acid. Arachidonic acid is subsequently metabolized along two principal enzymatic branches:

1. Cyclooxygenase (COX) Pathway: Synthesizes prostaglandins ($PGE_2, PGD_2$), prostacyclin ($PGI_2$), and thromboxane $A_2$ ($TXA_2$).
2. Lipoxygenase (5-LOX) Pathway: Synthesizes leukotrienes ($LTB_4, LTC_4, LTD_4, LTE_4$).

$\text{Membrane Phospholipids} \xrightarrow[\textbf{Inhibited by Corticosteroids / Annexin A1}]{\text{Phospholipase } A_2} \text{Arachidonic Acid} \xrightarrow[\textbf{Inhibited by NSAIDs}]{\text{COX-1 / COX-2}} \text{Prostaglandins \& } TXA_2$

Cyclooxygenase-1 (COX-1) vs. Cyclooxygenase-2 (COX-2)

• COX-1 (Constitutive): Expressed continuously in virtually all tissues, particularly gastric mucosal epithelium, renal parenchyma, vascular endothelium, and platelets. Functions:
  • Gastroprotection: Generates $PGE_2$ and $PGI_2$, which stimulate gastric mucus and bicarbonate secretion, decrease gastric acid production, and maintain mucosal capillary blood flow.
  • Platelet Aggregation: Platelet COX-1 synthesizes Thromboxane $A_2$ ($TXA_2$), a potent platelet activator and vasoconstrictor.
• COX-2 (Inducible): Induced transiently by pro-inflammatory cytokines ($IL-1, TNF-\alpha$), endotoxins, and growth factors at sites of inflammation, pain, and surgical trauma. Functions:
  • Hyperalgesia & Erythema: Generates $PGE_2$ and $PGI_2$, which sensitize peripheral nociceptors to bradykinin and histamine, and mediate central fever at the preoptic hypothalamus.
  • Endothelial Antithrombosis: Vascular endothelial COX-2 produces Prostacyclin ($PGI_2$), which promotes vasodilation and potently inhibits platelet aggregation.
  • Constitutive Renal COX-2: Present in the renal macula densa, regulating renin release and medullary hemodynamics.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

1. Non-Selective COX-1 & COX-2 Inhibitors

Exemplar agents: Ibuprofen, Naproxen, Indomethacin, Ketorolac, Meloxicam (relative COX-2 preference at low doses), and Sulindac.

• Therapeutic Actions: Analgesia (mild-to-moderate musculoskeletal pain), antipyresis (fever reduction), and anti-inflammatory action (attenuates perioperative foot and ankle edema).
• Gastrointestinal Toxicity: Unopposed blockade of constitutive gastric COX-1 reduces $PGE_2$ and $PGI_2$, compromising the gastric mucosal protective layer and causing gastric erosions, peptic ulcer disease, and life-threatening gastrointestinal hemorrhage. Risk is compounded by advanced age, prolonged duration, and concomitant anticoagulation. Gastroprotection: Co-prescribe a Proton Pump Inhibitor (PPI, e.g., omeprazole) or Misoprostol (synthetic $PGE_1$ analog).
• Renal Hemodynamic Toxicity: Renal prostaglandins ($PGE_2, PGI_2$) act directly to dilate the afferent renal arterioles, preserving renal blood flow and Glomerular Filtration Rate (GFR). NSAIDs block afferent arteriolar dilation, precipitating afferent vasoconstriction, decreased GFR, and Acute Prerenal Azotemia / Acute Kidney Injury (AKI).
  • The "Triple Whammy": Co-administration of an NSAID + ACE inhibitor (or ARB) + Diuretic. Diuretics induce hypovolemia; ACE inhibitors block angiotensin II-mediated efferent arteriolar constriction (dilating the efferent arteriole); NSAIDs constrict the afferent arteriole. The combined drop in transcapillary glomerular hydrostatic pressure causes catastrophic acute renal failure.
  • Chronic NSAID abuse can lead to Renal Papillary Necrosis and Acute Interstitial Nephritis (AIN).

High-Yield Specific NSAIDs in Podiatry

• Ketorolac (Toradol): Exceptionally potent parenteral (IV/IM) NSAID with analgesic efficacy comparable to moderate-dose opioids. Strict Clinical Rule: Therapy is limited to a maximum of 5 consecutive days due to a dramatic, unacceptable risk of severe peptic ulceration, gastrointestinal perforation, and acute renal tubular necrosis.
• Indomethacin: Potent, non-selective NSAID historically favored for acute gouty arthritis and closure of patent ductus arteriosus (PDA). High-yield adverse effect: severe frontal throbbing headaches, dizziness, and neuropsychiatric confusion in up to $25\%$ of patients (due to structural similarity to serotonin).
• Sulindac: Prodrug; metabolized to an active sulfide metabolite. Undergoes enterohepatic circulation. Associated with lower renal prostaglandin inhibition ("spares the kidney" in mild disease), but still carries classic NSAID toxicities.

2. Selective COX-2 Inhibitors: Celecoxib (Celebrex)

Celecoxib possesses a diaryl-substituted pyrazole structure that selectively binds the unique, larger, flexible side pocket of inducible COX-2, sparing constitutive COX-1 at therapeutic concentrations.

• Clinical Benefit: Delivers anti-inflammatory and analgesic efficacy equivalent to non-selective NSAIDs with a significantly lower incidence of gastric ulceration, dyspepsia, and GI bleeding; does not impair platelet aggregation.
• Cardiovascular Thrombotic Hazard: By selectively inhibiting endothelial COX-2, celecoxib halts the production of vasodilatory, anti-aggregatory Prostacyclin ($PGI_2$). However, platelet COX-1 remains completely uninhibited, leaving platelet Thromboxane $A_2$ ($TXA_2$) generation entirely intact. This profound biochemical imbalance creates an intense prothrombotic, vasoconstrictive state, markedly elevating the relative risk of myocardial infarction, stroke, systemic hypertension, and cardiovascular mortality.
• Sulfa Moiety: Celecoxib contains a sulfonamide side chain and is contraindicated in patients with severe sulfonamide hypersensitivity.

3. Aspirin (Acetylsalicylic Acid / ASA)

Aspirin is unique among NSAIDs: it binds covalently and irreversibly acetylates a specific serine residue in the active sites of both COX-1 (Ser529) and COX-2 (Ser516).

• Platelet Specificity: Platelets are anucleate cell fragments lacking ribosomes and cannot synthesize new cyclooxygenase enzymes. Thus, a single low dose of aspirin ($81\text{ mg}$) irreversibly disables platelet COX-1 for the entire circulating lifespan of the platelet (7 to 10 days). Vascular endothelial cells possess nuclei and can synthesize new COX-2 within hours to restore $PGI_2$ production.
• Salicylate Toxicity (Overdose): Toxic ingestions manifest as a characteristic biphasic, mixed acid-base disorder:
  1. Respiratory Alkalosis (Early): Direct salicylate stimulation of the medullary respiratory center induces intense hyperventilation, blowing off $CO_2$ (decreased $PaCO_2$, elevated blood pH).
  2. High Anion Gap Metabolic Acidosis (Late): Salicylates uncouple mitochondrial oxidative phosphorylation, halting ATP production. This shifts cellular metabolism to anaerobic glycolysis, producing massive accumulation of lactic acid, ketoacids, and salicylic acid.
  • Symptoms: Tinnitus, vertigo, hyperpyrexia, confusion, tachypnea, coma.
  • Treatment: Alkalinization of urine with intravenous Sodium Bicarbonate ($NaHCO_3$). Raising tubular urine pH above $7.5$ shifts salicylic acid into its charged, ionized conjugate base ($A^-$), trapping it in the tubular lumen (ion trapping) and accelerating renal excretion; hemodialysis for severe levels.
• Reye Syndrome: Administration of aspirin to children or adolescents recovering from viral infections (influenza, varicella) triggers acute fulminant hepatic microvesicular steatosis, hyperammonemia, and encephalopathy. (Acetaminophen is the antipyretic of choice in children).

---

Acetaminophen (Paracetamol / APAP)

Acetaminophen produces effective central analgesia and antipyresis; however, it lacks significant peripheral anti-inflammatory activity and does not inhibit peripheral platelet aggregation or cause gastric erosion.

• Mechanism: Reversible inhibition of central nervous system cyclooxygenase (COX-3 or peroxidase active sites) and modulation of endogenous cannabinoid/cannabinoid-1 ($CB_1$) receptors.
• Hepatic Metabolism & The NAPQI Pathway:
  • At therapeutic doses, $90 - 95\%$ of acetaminophen is safely conjugated in the liver via Phase II Glucuronidation and Sulfation into non-toxic, water-soluble metabolites excreted in urine.
  • Approximately $5\%$ is metabolized by the hepatic Cytochrome P450 2E1 (CYP2E1) pathway into a highly reactive, toxic electrophilic intermediate: NAPQI (N-acetyl-p-benzoquinone imine).
  • Under normal conditions, intracellular Glutathione (GSH) immediately conjugates NAPQI, converting it into harmless mercapturic acid conjugates.

                         Acetaminophen Hepatic Metabolism
    
                          Acetaminophen (Therapeutic Dose)
                           │                         │
          (90 - 95%)       ▼                         ▼    (5% via CYP2E1)
      Phase II Conjugation                    Toxic Intermediate: NAPQI
     (Glucuronide / Sulfate)                         │
                           │                         ▼  ◄── Glutathione (GSH)
                           ▼                Non-Toxic Mercapturate
                     Renal Excretion
    ────────────────────────────────────────────────────────────────────────
                          Acetaminophen (Toxic Overdose)
                           │
                           ▼
        Phase II Saturated + Glutathione Depleted (<30%)
                           │
                           ▼
         Unconjugated NAPQI Binds Hepatocyte Proteins
                           │
                           ▼
        Centrilobular Hepatic Necrosis & Fulminant Liver Failure
                           │
         [ANTIDOTE]: N-Acetylcysteine (NAC) Replenishes Glutathione

• Overdose Toxicology: In acute overdose ($>7.5 - 10\text{ g}$ in adults) or chronic alcoholism (where ethanol induces CYP2E1 and malnutrition depletes baseline glutathione), Phase II pathways become completely saturated. Excess NAPQI rapidly depletes hepatic glutathione stores. When glutathione falls below $30\%$ of baseline, free NAPQI binds covalently to sulfhydryl groups on hepatocyte membrane proteins, inducing oxidative stress, mitochondrial collapse, and centrilobular hepatic necrosis (Zone 3) and fulminant liver failure.
• Antidote Protocol: N-Acetylcysteine (NAC / Mucomyst). NAC provides sulfhydryl donors that directly replenish intracellular hepatic glutathione and acts as an alternate glutathione substitute to bind NAPQI. Administered orally or IV based on the Rumack-Matthew nomogram (evaluating plasma APAP levels vs. time since ingestion). Most effective when initiated within 8 hours.
• Maximum Daily Dose: Maximum recommended dose is $3,000 - 4,000\text{ mg/day}$ in healthy adults; reduced to $2,000\text{ mg/day}$ in elderly patients, chronic alcoholics, or pre-existing cirrhosis.

---

Opioid Analgesics: Receptor Signaling & Overdose Toxidrome

Opioid analgesics are indicated for acute, severe postoperative podiatric pain (e.g., following major reconstructive flatfoot surgery, hindfoot arthrodeses, or trauma). Agents include: Morphine, Oxycodone, Hydrocodone, Hydromorphone (Dilaudid), Fentanyl, and Tramadol.

Mechanism of Action: The Mu-Opioid Receptor Cascade

Opioids bind stereospecifically to endogenous $\mu$ (mu), $\kappa$ (kappa), and $\delta$ (delta) opioid receptors distributed along the spinal cord dorsal horn (substantia gelatinosa), periaqueductal gray (PAG), thalamus, and cortex. All opioid receptors are $G_i$-protein-coupled receptors:

1. Presynaptic Action: Inhibits adenylyl cyclase, decreasing intracellular $cAMP$, which closes voltage-gated $N$-type calcium channels, halting the exocytosis of excitatory neurotransmitters (Substance P, Glutamate).
2. Postsynaptic Action: Opens G-protein-inwardly rectifying potassium channels ($GIRK$), driving potassium efflux. This hyperpolarizes the postsynaptic neuronal membrane, rendering it refractory to nociceptive depolarization.

Pharmacologic Effects, Tolerance & Lack of Tolerance

• Analgesia, Sedation, Euphoria: Mediated by central mu receptors.
• Respiratory Depression: Decreases the sensitivity of brainstem respiratory centers to arterial carbon dioxide ($PaCO_2$); primary mechanism of lethality in overdose.
• High-Yield Board Pearl: Tolerance vs. Non-Tolerance:
  • Tolerance Develops to: Analgesia, euphoria, sedation, respiratory depression, nausea, and emesis (patients require increasing doses over time).
  • NO Tolerance Develops to:
    1. Miosis (Pinpoint Pupils): Mediated by parasympathetic stimulation of the Edinger-Westphal nucleus via the oculomotor nerve (CN III).
    2. Constipation (Opioid-Induced Constipation, OIC): Mediated by peripheral mu receptors in the enteric myenteric plexus (decreased propulsive peristalsis and increased circular sphincter tone). Every patient prescribed opioids must receive a prophylactic bowel regimen (stimulant laxative + stool softener). Stigmatized chronic addicts still have pinpoint pupils and constipation!
• Pruritus: Non-immunologic, direct histamine release from tissue mast cells (especially with morphine and codeine; fentanyl produces minimal histamine release).
• Tramadol: Dual mechanism—weak mu-opioid agonist AND inhibitor of serotonin and norepinephrine reuptake (SNRI action). Carries risk of seizures and Serotonin Syndrome if combined with SSRIs or MAOIs.

Opioid Overdose Triad & Antidote

$\textbf{The Classic Opioid Overdose Triad:} \quad \textbf{CNS Depression / Coma} + \textbf{Severe Respiratory Depression} + \textbf{Miosis (Pinpoint Pupils)}$

• Antidote: Naloxone (Narcan). A pure, competitive antagonist at mu, kappa, and delta opioid receptors. Administered IV, IM, or intranasally. Reverses respiratory depression within 1 to 2 minutes. Pharmacokinetic Warning: Naloxone has a short half-life ($30 - 90\text{ minutes}$); long-acting opioids (e.g., methadone, sustained-release oxycodone) will outlast naloxone, requiring repeated doses or continuous infusion to prevent recurrent fatal hypoventilation.

---

Corticosteroid Pharmacology in Podiatry

Synthetic glucocorticoids (Triamcinolone acetonide [Kenalog], Dexamethasone, Methylprednisolone [Depo-Medrol], Prednisone) are potent anti-inflammatory agents utilized extensively in podiatry via targeted local injection.

Molecular Mechanism of Glucocorticoid Action

Glucocorticoids are lipophilic molecules that diffuse across the plasma membrane and bind to the cytosolic Glucocorticoid Receptor (GR) complexed with heat-shock proteins (Hsp90). Upon ligand binding, Hsp90 dissociates, and the drug-receptor complex homodimerizes and translocates into the nucleus:

1. Transactivation: Binds to specific DNA sequences termed Glucocorticoid Response Elements (GREs) to induce gene transcription. High-yield target: induces Lipocortin-1 (Annexin A1), which directly binds and inhibits Phospholipase $A_2$ ($PLA_2$), shutting down the entire cascade of both prostaglandins and leukotrienes.
2. Transrepression: Directly binds and physically inhibits pro-inflammatory transcription factors, chief among them Nuclear Factor Kappa B (NF-$\kappa$B) and Activator Protein 1 (AP-1). This halts the synthesis of inflammatory cytokines ($IL-1, IL-2, IL-6, TNF-\alpha$), chemokines, inducible nitric oxide synthase (iNOS), and COX-2.

Podiatric Indications & Local Injection Complications

• Indications: Plantar fasciitis, Morton's intermetatarsal neuroma, sinus tarsi syndrome, 1st MTP synovitis, posterior tibial tendonitis (peritendinous only).
• High-Yield Local Complications:
  • Plantar Fat Pad Atrophy: Injection of triamcinolone into subcutaneous tissues inhibits fibroblast proliferation and extracellular matrix collagen synthesis, causing irreversible fat necrosis and thinning of the plantar heel or metatarsal fat pad, producing chronic, intractable metatarsalgia.
  • Cutaneous Hypopigmentation / Depigmentation & Telangiectasias: Occurs if steroid solution leaks into superficial dermis, suppressing melanocyte function (particularly prominent in darkly pigmented individuals).
  • Plantar Fascia Rupture / Tendon Rupture: Local collagen disruption drastically weakens tensile strength. Direct injection into the substance of the Achilles tendon is strictly contraindicated due to high risk of complete tendon rupture.
  • Iatrogenic Septic Arthritis: Introduction of skin flora into synovial space.
• Systemic Complications of Corticosteroid Therapy:
  • Acute hyperglycemia (stimulates gluconeogenesis, induces peripheral insulin resistance; high risk in diabetics).
  • Secondary adrenal insufficiency (abrupt cessation suppresses hypothalamic-pituitary-adrenal [HPA] axis; requires taper).
  • Osteoporosis and Avascular Necrosis (AVN) / Osteonecrosis of the femoral head and talus.
  • Cushingoid habitus, impaired wound healing, posterior subcapsular cataracts, peptic ulcers.

Anti-Gout Therapeutics: Acute vs. Chronic Management

Gout is a metabolic crystalline arthropathy characterized by hyperuricemia (serum urate $>6.8\text{ mg/dL}$) leading to precipitation of needle-shaped, negatively birefringent monosodium urate (MSU) crystals within articular and periarticular tissues. In podiatry, the classic presentation is podagra (acute exquisite inflammation of the first metatarsophalangeal joint in $>50\%$ of initial attacks).

Pathophysiology of the Acute Gout Flare

Free MSU crystals are phagocytosed by synovial resident macrophages, activating the intracellular NLRP3 Inflammasome complex. Active caspase-1 cleaves pro-IL-1$\beta$ into mature Interleukin-1$\beta$ ($IL-1\beta$), triggering intense endothelial activation, massive release of chemokines (IL-8), and explosive recruitment of neutrophils into the joint space. Ingesting crystals causes neutrophil activation, degranulation, release of proteases, reactive oxygen species, and acute synovitis.

                                Gout Therapeutic Algorithm
    
          ACUTE GOUT FLARE                            CHRONIC GOUT / ULT
    (Goal: Halt Synovial Inflammation)          (Goal: Lower Urate <6.0 mg/dL)
                 │                                             │
      ┌──────────┼──────────┐                      ┌───────────┼───────────┐
      ▼          ▼          ▼                      ▼           ▼           ▼
    NSAIDs   Colchicine  Steroids             Allopurinol  Probenecid  Pegloticase
    (Naproxen) (Binds    (PO Prednisone /     (Inhibits    (Inhibits   (Recombinant
               Tubulin)   IA Kenalog)          Xanthine     URAT1 in    Uricase:
                                               Oxidase)     Proximal    Urate →
                                                            Tubule)     Allantoin)
    ────────────────────────────────────────────────────────────────────────
    KEY RULE: Do not stop established Urate-Lowering Therapy during a flare.
    Start ULT low and give Colchicine/NSAID prophylaxis for 3 to 6 months.

1. Acute Gout Flare Management

2. Chronic Urate-Lowering Therapy (ULT)

Indications for ULT: $\ge 2$ gout flares per year, presence of subcutaneous tophi, radiographic evidence of gouty joint erosion (overhanging margins / "rat-bite" erosions), or history of uric acid nephrolithiasis. Target serum urate is $<6.0\text{ mg/dL}$ ($<5.0\text{ mg/dL}$ if tophi present).

Xanthine Oxidase Inhibitors (XOIs)

Uric acid is the end-product of purine degradation: $\text{Hypoxanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Xanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid}$.

• Allopurinol: Purine analog; competitive inhibitor of xanthine oxidase at low doses; metabolized by XO to oxypurinol (alloxanthine), which acts as a long-acting, non-competitive inhibitor of xanthine oxidase. First-line ULT for all patients.
  • High-Yield Pharmacogenetic Screening: $HLA-B^*58:01$ allele testing is recommended before starting allopurinol in patients of Southeast Asian (Han Chinese, Korean, Thai) descent and in African American patients (2020 ACR guideline). Patients with this allele possess an extraordinary risk of developing Allopurinol Hypersensitivity Syndrome / SCAR (Severe Cutaneous Adverse Reactions), including DRESS syndrome and Stevens-Johnson Syndrome (SJS/TEN) with high mortality.
  • Fatal Drug Interaction with Azathioprine & 6-Mercaptopurine: Azathioprine is a purine antimetabolite prodrug converted to 6-mercaptopurine (6-MP). The primary inactivation pathway for 6-MP is oxidation catalyzed by Xanthine Oxidase. Co-administration of allopurinol blocks 6-MP degradation, driving serum 6-MP concentrations to catastrophic, lethal levels, causing pancytopenia and fatal bone marrow failure. If co-prescribed, the azathioprine/6-MP dose must be reduced by $75\%$.
• Febuxostat (Uloric): Non-purine selective inhibitor of xanthine oxidase. Used in allopurinol intolerance or renal insufficiency. Carries an FDA black box warning for increased risk of cardiovascular death compared to allopurinol.

Uricosuric Agents: Probenecid

• Mechanism: Inhibits the Urate Anion Transporter 1 (URAT1) and organic anion transporter 4 (OAT4) in the apical brush border of the renal proximal convoluted tubule, blocking the reabsorption of filtered uric acid and accelerating urinary excretion.
• Contraindications: Ineffective in moderate-to-severe renal impairment ($GFR < 30 - 50\text{ mL/min}$). Strictly contraindicated in patients with a history of uric acid nephrolithiasis (renal calculi) or urate overproduction.
• Historical Beta-Lactam Interaction: Probenecid also competitively inhibits basolateral organic anion transporters (OAT1/OAT3), blocking the active tubular secretion of Penicillins and Cephalosporins. Historically co-administered with penicillin to intentionally prolong beta-lactam half-life and maintain high plasma levels.

Recombinant Uricase: Pegloticase (Krystexxa)

• Mechanism: Recombinant porcine-derived uricase (urate oxidase) enzyme covalently attached to monomethoxypolyethylene glycol (PEG). Converts poorly soluble uric acid into Allantoin, an inert, highly water-soluble metabolite readily excreted by the kidneys.
• Application: Reserved for refractory, severe chronic tophaceous gout failing maximum-dose oral XOIs. Administered as IV infusion every 2 weeks. Risk of anaphylaxis and infusion reactions ($10\%$) due to development of anti-drug antibodies.